PNC-27 Research Overview (also known as PNC27, p53-derived anticancer peptide)
A p53-derived chimeric peptide that selectively induces apoptosis in cancer cells while leaving normal cells unaffected. PNC-27 contains the MDM2-binding domain of p53 fused to a membrane-penetrating leader sequence, allowing it to insert into cancer cell membranes and trigger selective pore formation and necrosis in transformed cells.
What Is PNC-27?
PNC-27 is a chimeric peptide designed around two functional domains: a 12-amino-acid leader sequence from the signal peptide of human h-ras (for membrane targeting) fused to amino acids 12–26 of the p53 tumor suppressor protein — the region that interacts with MDM2. In cancer cells, MDM2 is overexpressed on the plasma membrane, where PNC-27 binds and initiates membrane disruption. Normal cells, which do not express membrane-associated MDM2, are not affected.
Mechanism of Selective Cytotoxicity
PNC-27's selectivity for cancer cells stems from differential membrane expression of HDM2 (the human homolog of MDM2). In transformed cells, HDM2 is constitutively expressed on the outer plasma membrane surface. PNC-27 binds this membrane-bound HDM2, inserts into the lipid bilayer, and forms pores — causing rapid cell death via membranolysis. Normal, non-transformed cells lack this membrane HDM2 expression and are therefore resistant.
Cancer Models Studied
PNC-27 has been tested in cell lines and animal models of pancreatic cancer, breast cancer, leukemia, melanoma, and lung adenocarcinoma. Across these models it has consistently shown potent and selective cytotoxic activity against cancer cells with no significant toxicity to normal cells.
Research Status
PNC-27 remains in preclinical research. Its non-receptor mechanism of action — membrane disruption rather than intracellular pathway modulation — distinguishes it from conventional cancer therapeutics and has generated interest as a scaffold for novel anticancer agents.
Quick Reference
| Literature-Reported Dose Range | 100-500mcg once daily |
| Literature-Reported Frequency | Once daily |
| Literature-Reported Cycle Length | 8-12 weeks (unvalidated community protocol) |
| Literature-Reported Washout | No established protocol |
| Storage | -20°C (powder) / 2-8°C (reconstituted) |
| Timing | Consistent daily timing |
Research Indications
Anticancer
Multi-Cancer Selectivity
Preclinical efficacy against pancreatic, breast, melanoma, leukemia, ovarian, and cervical cancers with no normal cell toxicity
p53-Independent Mechanism
Targets membrane HDM-2 and works in p53-mutant cancers, unlike intracellular HDM-2 inhibitors
Chemotherapy Synergy
Documented synergy with paclitaxel and ketone bodies, potential for combination approaches
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Research Protocol | 100-500mcg | Once daily | SubQ |
Timing
Recommended administration window: consistent daily timing. Typical onset: no established human efficacy timeline.
Peptide Interactions
Ex vivo studies on patient-derived ovarian cancer cells demonstrated synergy via isobologram analysis. Cancer cells surviving paclitaxel upregulate membrane MDM-2, increasing PNC-27 susceptibility.
2025 peer-reviewed study showed lithium acetoacetate and beta-hydroxybutyrate reduce PNC-27 IC50 by 200-400% via Warburg effect disruption. Ketogenic diet may theoretically enhance efficacy.
No direct interaction studies. Both have anticancer mechanisms — TA1 via immune modulation, PNC-27 via direct membranolysis. Theoretically complementary but unstudied.
Paclitaxel synergy is documented. Other chemotherapies are unstudied but mechanistically compatible given PNC-27's distinct membrane-lytic action.
No interaction data. PNC-27 induces necrosis which releases tumor antigens, theoretically enhancing immune recognition. Pure speculation — no studies exist.
Small molecule HDM-2 inhibitors act intracellularly on wild-type p53 tumors. PNC-27 targets membrane HDM-2 and works in p53-mutant cancers. Potential for additive effects but unstudied.
No documented interactions with common healing peptides. Different mechanisms and targets. No basis for interaction concern, but no studies confirm safety of combination.
Reported Research Timeline
01No established human efficacy timeline — all data is preclinical
02Preclinical: Cancer cell death in 90 minutes at effective concentrations
03Injection site reactions are the most commonly reported side effect
04FDA has warned against PNC-27 use — proceed with extreme caution
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
NOT FDA approved — explicit FDA warning issued against use
No verified human clinical trial data in peer-reviewed journals
No published human pharmacokinetic data
Contamination found in marketed products (FDA warning)
Should never replace FDA-approved cancer treatments
Discuss with oncologist before any consideration of use
Seek Medical Attention If:
Signs of infection at injection site
Allergic reaction or systemic illness
Any unexpected adverse effects
Worsening of cancer symptoms
Quality Indicators
Acceptable Range
FDA Warning
FDA explicitly warns against PNC-27 use — not evaluated or approved
Verified Marker
Third-Party Testing
Verify purity and sterility through independent COA
Quality Concern
Inhalable Products
FDA cited contaminated inhalable PNC-27 — avoid nebulized forms
Research Citations
- Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes
Sarafraz-Yazdi E, Mumin S, Engel D, et al., 2010, Proceedings of the National Academy of Sciences - The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide
Sarafraz-Yazdi E, Bowne WB, Engel D, et al., 2010, Cancer Chemotherapy and Pharmacology - PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis
Sarafraz-Yazdi E, Fridman D, Lin B, et al., 2022, Biomedicines - Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption
Pincus MR, Sarafraz-Yazdi E, et al., 2024, Annals of Clinical & Laboratory Science - PNC-27 Kills Cervical Cancer Cells but Not Untransformed Cervical Cells, an Effect that is Enhanced by Ketone Bodies
Pincus MR, Bowne W, Silberstein M, Sarafraz-Yazdi E, 2025, Medical Research Archives - Ex vivo Efficacy of Anti-Cancer Drug PNC-27 in the Treatment of Patient-Derived Epithelial Ovarian Cancer
Kanovsky M, Raffo A, Drew L, et al., 2015, Annals of Clinical & Laboratory Science - Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells
Sarafraz-Yazdi E, et al., 2020, Anticancer Research - Conjugated PNC-27 peptide/PEI-superparamagnetic iron oxide nanoparticles (SPIONs) as a double targeting agent for early cancer diagnosis: In vitro study
Rahmani R, Darroudi M, Gharanfoli M, 2022, Iran J Basic Med Sci - The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide
Sookraj KA, Bowne WB, Adler V, 2010, Cancer Chemother Pharmacol - Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes
Sarafraz-Yazdi E, Bowne WB, Adler V, 2010, Proc Natl Acad Sci U S A - The penetratin sequence in the anticancer PNC-28 peptide causes tumor cell necrosis rather than apoptosis of human pancreatic cancer cells
Bowne WB, Sookraj KA, Vishnevetsky M, 2008, Ann Surg Oncol - Poptosis or Peptide-Induced Transmembrane Pore Formation: A Novel Way to Kill Cancer Cells without Affecting Normal Cells
Pincus MR, Silberstein M, Zohar N, 2024, Biomedicines
Research Focus
Cancer cell apoptosis, Tumor biology, Selective cytotoxicity, p53 pathway, Oncology research
Verified Vendors Carrying PNC-27
Frequently Asked Questions
What should researchers watch for with PNC-27?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with PNC-27?
No established human efficacy timeline — all data is preclinical
How is PNC-27 typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →